Methsuximide
Celontin (methsuximide) is a small molecule pharmaceutical. Methsuximide was first approved as Celontin on 1982-01-01. It is used to treat absence epilepsy and epilepsy in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Celontin (generic drugs available since 2023-05-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methsuximide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CELONTIN | Pfizer | N-010596 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| celontin | New Drug Application | 2018-08-03 |
| methsuximide | ANDA | 2023-05-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| absence epilepsy | HP_0011147 | D004832 | G40.A |
| epilepsy | EFO_0000474 | D004827 | G40.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
METHSUXIMIDE, METHSUXIMIDE, NOVITIUM PHARMA | |||
| 2023-10-28 | CGT | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | D89.81 | — | 6 | 1 | — | — | 7 | |
| Lymphoma | D008223 | C85.9 | — | 1 | 1 | — | — | 2 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 1 | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | 1 | — | — | — | 2 |
| Sarcoma | D012509 | — | 1 | — | — | — | 1 | ||
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | 1 | |
| Hematologic neoplasms | D019337 | 1 | 1 | — | — | — | 1 | ||
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | — | — | — | 1 |
| Epidermolysis bullosa acquisita | D016107 | L12.3 | — | 1 | — | — | — | 1 | |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | 1 | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHSUXIMIDE |
| INN | mesuximide |
| Description | Methsuximide is an organic molecular entity. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1C(=O)CC(C)(c2ccccc2)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 77-41-8 |
| RxCUI | 47858 |
| ChEMBL ID | CHEMBL697 |
| ChEBI ID | — |
| PubChem CID | 6476 |
| DrugBank | DB05246 |
| UNII ID | 0G76K8X6C0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 189 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
495 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more